pegvisomant

The drug is intended for the treatment of acromegaly in patients for whom surgery or radiotherapy has not been successful, or if these methods cannot be applied. The goal of treatment is to normalize blood levels of insulin-like growth factor 1 (IGF-1).

Form: lyophilisate for solution for injection

ATC: H01AX01

Manufacturer: Pfizer Manufacturing Belgium NV (manufacturing, quality control and batch release of water for injections in pre-filled syringes, simultaneous packaging and labeling of water for injections and medicinal product; manufacturing medicinal product in bulk and primary packaging; batch release of medicinal product; quality control of medicinal product, excluding the 'Bioassay' test)

The drug is intended for the treatment of acromegaly in patients for whom surgery or radiotherapy has not been successful, or if these methods are not possible. The goal of treatment is to normalize blood levels of insulin-like growth factor 1 (IGF-1).

Form: lyophilisate for solution for injection

ATC: H01AX01

Manufacturer: Pfizer Manufacturing Belgium NV (manufacturing, quality control and batch release of water for injections in pre-filled syringes, simultaneous packaging and labeling of water for injections and medicinal product; manufacturing of medicinal product in bulk and primary packaging; batch release of medicinal product; quality control of medicinal product, excluding the 'Bioassay' test)

The drug is intended for the treatment of acromegaly in patients for whom surgery or radiotherapy has not been successful, or if these methods cannot be applied. The goal of treatment is to normalize blood levels of insulin-like growth factor 1 (IGF-1).

Form: lyophilisate for solution for injection

ATC: H01AX01

Manufacturer: Pfizer Manufacturing Belgium NV (manufacturing, quality control and batch release of water for injections in pre-filled syringes, simultaneous packaging and labeling of water for injections and medicinal product; manufacturing of medicinal product in bulk and primary packaging; batch release of medicinal product; quality control of medicinal product, excluding the 'Bioassay' test)

The drug is intended for the treatment of acromegaly in patients for whom surgery or radiotherapy has not been successful, or if these methods are not possible. The goal of treatment is to normalize blood levels of insulin-like growth factor 1 (IGF-1).

Form: lyophilisate for solution for injection

ATC: H01AX01

Manufacturer: Pfizer Manufacturing Belgium NV (manufacturing, quality control and batch release of water for injections in pre-filled syringes, simultaneous packaging and labeling of water for injections and medicinal product; manufacturing of medicinal product in bulk and primary packaging; batch release of medicinal product; quality control of medicinal product, excluding the 'Bioassay' test)